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Abstract 
Introduction: The highly selective ALK inhibitor alectinib is standard therapy for ALK-
positive lung cancers; however, some tumors quickly develop resistance. Here, we investigated 
the mechanism associated with rapid acquisition of resistance using clinical samples.  
Methods: Autopsied samples were obtained from lung, liver, and renal tumors from a 51-
year-old male patient with advanced ALK-positive lung cancer and who had acquired resistance 
to alectinib in only 3 months. We established an alectinib-resistant cell line (ABC-14) from 
pleural effusion and an alectinib/crizotinib-resistant cell line (ABC-17) and patient-derived 
xenograft (PDX) model from liver tumors. Additionally, we performed next-generation 
sequencing (NGS), direct DNA sequencing, and quantitative real-time reverse-transcription 
polymerase chain reaction. 
Results: ABC-14 cells harbored no ALK mutations and were sensitive to crizotinib while 
also exhibiting MET gene amplification and amphiregulin overexpression. Additionally, 
combined treatment with crizotinib/erlotinib inhibited cell growth. ABC-17 and PDX tumors 
harbored ALK G1202R, and PDX tumors metastasized to multiple organs in vivo, whereas the 
third generation ALK-inhibitor, lorlatinib, diminished tumor growth in vitro and in vivo. NGS 
indicated high tumor mutation burden (TMB) and heterogeneous tumor evolution. The 
autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and the right renal metastasis 
harbored ALK G1202R (c. 3604 G>C); the mutation thus comprised different codon changes.  
Conclusions: High TMB and heterogeneous tumor evolution might be responsible for rapid 
acquisition of alectinib resistance. Timely lorlatinib administration or combined therapy with 
an ALK inhibitor and other receptor tyrosine-kinase inhibitors might constitute a potent 
strategy. 
Keywords: NSCLC, alectinib, ALK G1202R, MET, amphiregulin 
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Introduction 
Molecular therapies targeting gene alterations of driver oncogenes, such as epidermal growth 
factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), are standard treatment 
strategies for advanced non-small cell lung cancer (NSCLC).1 The second-generation ALK 
inhibitor alectinib shows a high objective response rate (93.5%) and a long progression-free 
survival (PFS) rate (3-year PFS: 62%) for ALK-positive NSCLC2; however, a portion of 
patients rapidly acquire resistance to alectinib within 3 months.3, 4  
To date, several mechanisms of resistance to alectinib, such as ALK mutations, have been 
reported in clinical samples. Resistance mutations in the ALK kinase domain, such as G1202R, 
are more frequently detected in tumors treated with alectinib (29%) relative to those treated 
with crizotinib (2%)5; however, the mechanisms underlying this rapid acquisition of resistance 
to alectinib have yet to be clarified.  
Here, we investigated the mechanism associated with rapid acquisition of resistance to 
alectinib using patient-derived samples, including autopsied tissues. All samples were collected 
from a single patient with NSCLC harboring echinoderm microtubule-associated protein-like 
4 (EML4)-ALK fusion genes and who responded to alectinib immediately as an initial treatment, 
albeit quickly acquired resistance. We comprehensively analyzed multiple clinical samples of 
pre- and post-alectinib treatment using next-generation sequencing (NGS) and performed in 
vitro and in vivo experiments using novel cell lines or a patient-derived xenograft (PDX) model. 
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Materials and Methods 
Detailed information is provided in the Supplementary Information. 
 
In vitro experiments and xenograft models 
Cell culture, western blot, and immunohistochemistry were performed, as previously 
described.6 The animal experimental protocol was approved by the Animal Care and Use 
Committee, Okayama University (Okayama, Japan) (OKU-2017084, 2017085).  
 
NGS and tumor mutation burden (TMB) analysis 
cDNA libraries were prepared using the TruSeq RNA Access library prep kit (Illumina, San 
Diego, CA, USA), and RNA sequencing was performed on a HiSeq sequencing system 
(Illumina). An unrooted phylogenetic tree was analyzed and displayed using the hclust, 
as.phylo, and plot functions under the RStudio environment (https://www.rstudio.com/). TMB 
was calculated for the selected 341 genes using MSK-IMPACT version 1.0 according to a 
previous report.7  
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Results 
Clinical course of the patient and sample collection 
A 51-year-old male patient (ex-smoker; 32 pack years) with no history of prior malignancies 
or radiation or chemotherapy was hospitalized in the coronary care unit due to pericardial 
effusion and acute heart failure (Fig. 1A). Computed tomography detected right-middle lung 
tumors with bilateral plural effusion and multiple liver tumors. Brain magnetic resonance 
imaging (MRI) showed metastatic lesions (Supplementary Fig. S1), and after drainage of the 
pericardial effusion, transbronchial biopsy of the primary lung tumor revealed adenocarcinoma 
with upregulated levels of the ALK protein and ALK translocation confirmed by fluorescence 
in situ hybridization (FISH) (Fig. 1B and Supplementary Fig. S2A). Alectinib (600 mg/day) 
inhibited lung tumor growth according to Response Evaluation Criteria in Solid Tumor version 
1.1 criteria describing partial response (RECIST PR) (Supplementary Table S1), and the patient 
was discharged from the hospital 20 days after alectinib administration. However, metastatic 
liver tumors quickly regrew only 3 months later (Fig. 1C). After four cycles of administration 
of cisplatin (75 mg/m2) plus pemetrexed (500 mg/m2), followed by two cycles of maintenance 
therapy with pemetrexed (best overall response: RECIST PR) (Supplementary Table S2), 
another ALK inhibitor, ceritinib (750 mg/day), was administrated for 1 month but showed little 
effect on tumor growth and was accompanied by intolerable toxicity  (Supplementary Table 
S3). Crizotinib (500 mg/day) was then administered, resulting in slightly reductions in the 
pleural effusion but lymphangitic carcinomatosis of the right lung, although progression of 
multiple liver metastases was observed. The small brain metastases identified in the temporal 
lobe and parietal lobe at diagnosis improved after 1.5 months of alectinib treatment. Prior to 
initiating ceritinib therapy, the metastases regrew; however, after ceritinib therapy, these lesions 
were not clear in the brain MRI image (Supplementary Fig. S1). The patient survived with lung 
cancer for only 12 months, and an autopsy was performed following family consent. The blood 
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sample for circulating tumor DNA analysis could not be obtained during the clinical course.  
We established two cell lines: the first (ABC-14) from pleural effusion and the other (ABC-
17) from PDX tumors from liver lesions generated using NOD/Shi-scid/IL-2Rγnull (NOG) mice 
(Fig. 1A and Supplementary Fig. S2B). The ALK fusion gene and upregulated levels of the 
ALK protein were confirmed in ABC-14, ABC-17, PDX tumors, and all autopsy specimens 
(lung, liver, and kidney) by immunohistochemistry or direct sequencing (Fig. 1B and 
Supplementary Fig. S2C). A common B-cell lymphoma-2-like 11-gene deletion, known as an 
intrinsic resistance mechanism to tyrosine kinase inhibitors (TKIs), was not found in either the 
ABC-14 or ABC-17 cell line (Supplementary Figs. S3A and B).8 
 
Activation of EGFR/MET signaling in ABC-14 cells and presence of the ALK mutation 
resulting in the G1202R substitution in ABC-17 cells 
Consistent with the clinical course, alectinib had limited inhibitory effect on in vitro cell 
proliferation (Figs. 2A and 3A) and the phosphorylation of ALK, signal transducer and 
activator of transcription 3 (STAT3), AKT, and extracellular signal-regulated kinase (ERK)1/2 
(Figs. 2B and 3B) in ABC-14 and ABC-17 cells. NGS suggested that mRNA levels of MET 
proto-oncogene receptor tyrosine kinase (MET) and the EGFR ligand amphiregulin AREG 
were elevated in ABC-14 cells (Supplementary Fig. S4A), with MET amplification confirmed 
by FISH (MET/CEP7 ratio, 5.6) and MET activation confirmed at the protein level (Figs. 2C 
and D; Supplementary Figs. S5A and B). Additionally, we confirmed increased AREG 
secretion (Fig. 2E). Consistently, we observed the synergistic effect of combined therapy with 
the ALK/MET inhibitor crizotinib and the EGFR TKI erlotinib or triple therapy with alectinib, 
erlotinib, and the MET inhibitor SGX-523 in ABC-14 cells in vitro and in vivo (Figs. 2F‒H and 
Supplementary Fig. S5D). 
NGS and direct sequencing of the ALK kinase domain revealed that both ABC-17 cells and 
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PDX tumors harbored a point mutation (G1202R) (Fig. 3C and Supplementary Fig. S4B). 
Moreover, we found that ABC-17 cells did not display elevated MET expression or MET 
protein levels, and that MET phosphorylation was also not activated (Supplementary Fig. S5C). 
As previously reported,9 lorlatinib treatment strongly inhibited cell proliferation in vitro (IC50 
= 65 nM) ALK, STAT3, AKT, and ERK1/2 phosphorylation in ABC-17 cells (Figs. 3D and E). 
Furthermore, lorlatinib treatment showed much stronger effects in ABC-17 tumors as 
compared with alectinib or crizotinib treatment in vivo (Fig. 3F).  
 
Lorlatinib diminishes PDX tumors with metastatic capability in NOG mice 
We then analyzed the metastatic capability of tumors in the PDX model using NOG mice. 
Interestingly, 10 weeks after tumor injection, mice developed multiple metastatic lesions in the 
lung, liver, spleen, and adrenal gland (Figs. 4A and B). Metastatic lesions were more frequently 
detected in PDX mice as compared with those in NOG mice xenografted using ABC-14 or 
ABC-17 cells (Fig. 4C). 
The epithelial-to-mesenchymal transition reportedly plays a role in the metastatic ability of 
cancer cells.10 We found that ABC-17 cells showed decreased E-cadherin and increased 
vimentin levels (Supplementary Figs. S6A and B), and that compared with ABC-17 cells, PDX 
tumors or tissue from autopsied liver metastatic lesions contained fewer vimentin-positive cells 
(Supplementary Figs. S4A, S6A, and S6B), whereas vimentin was observed in stromal cells 
from PDX tumors. A previous study suggested that vimentin-positive stromal cells might 
potentially affect metastatic ability.11 We then determined the efficacy of lorlatinib treatment in 
PDX tumors, finding that lorlatinib diminished tumor growth and lung metastasis almost 
completely without loss of body weight, whereas neither alectinib nor crizotinib treatment 
showed any effect on tumor growth or metastatic ability (Fig. 4D). 
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Heterogeneous tumor evolution and high TMB 
A recent study revealed that TMB negatively affects the duration of treatment with driver 
oncoprotein inhibitors.12 Based on this finding, we assessed TMB in our samples using a 
previously described process7 by calculating TMB using 341 genes included in MSK-
IMPACT version 1.0. Briefly, we extracted the number of mutations in the selected genes 
from NGS data, and TMB was calculated by dividing the number of mutations by the total 
genomic area where the mutations were reported (0.98 Mb), with the threshold for high TMB 
defined as >13.8 mutations/Mb. Interestingly, pretreatment samples and autopsied tumors 
showed high TMB (≥25 mutations/Mb) (Fig. 5A). Moreover, the mutation pattern did not 
indicate a smoking signature (Supplementary Table. S4 and S5), microsatellite regions were 
stable, and we detected no mutation of DNA polymerase epsilon (POLE) or defects in genes 
associated with DNA-damage repair (DDR), although expression levels of some DDR genes, 
such as poly(ADP-ribose) polymerase 1 (PARP1) and X-ray repair cross-complementing 1, 
were elevated (Supplementary Fig. S7A). 
We then assessed the evolution of the resistant tumors. The EML4-ALK fusion (variant 
3a/3b) was confirmed in all samples (Supplementary Fig. S2C), with mRNA-expression 
profiles varying between pretreatment samples and post-treatment autopsied samples 
(Supplementary Figs. S7B, 7C). These results might suggest that the tumor evolved 
heterogeneously. The ALK mutation resulting in the G1202R substitution and resistance was 
detected in ABC-17 cells, PDX tumors, as well as autopsied liver samples, right middle lung 
tumors, and right renal tumors; however, it was not detected in ABC-14 cells, the plural 
effusion from which the ABC-14 cells was derived, or left renal tumors (Supplementary Figs. 
S4B‒D, S8A and S8B). This result suggested that cancer cells harboring the ALK G1202R 
mutation existed heterogeneously in each metastatic site. Additionally, we found that the 
associated ALK mutations comprised different codon changes at different sites (i.e., primary 
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lung: GGA to AGA; right renal metastasis: GGA to CGA) (Fig. 5B). Other types of 
secondary ALK mutation were not detected. 
Consequently, these data suggested that the ALK-positive lung cancer tumors displayed 
high TMB and evolved in various ways, and that heterogeneous drug-resistant clones existed 
in the same patient. 
 
Discussion 
Development of alternative treatment strategies for cases of rapid alectinib resistance 
represents an important clinical issue for lung cancers harboring ALK fusions. This study 
revealed the following major findings: 1) several resistant mechanisms, including activation of 
MET, EGFR, or resistant ALK G1202R mutation, can occur in the same patient 
(Supplementary Figs. 9A and B); 2) ALK G1202R was heterogeneously detected among 
autopsied samples, with this mutation the result of different codon changes (Fig. 5B); and 3) 
the tumors showed high TMB and heterogonous tumor evolution.  
Lung cancers with ALK fusions exhibit high diversity13; therefore, some patients might 
benefit from treatment with alectinib alone, whereas others, such as the patient described in the 
present study, might require other-generation ALK inhibitors or intensive combination 
therapies. It is possible that shifting of the therapeutic regimen to lorlatinib or a combination 
therapy at an appropriate time might have changed the outcome of the present case. In the 
future, it might be possible to select a suitable treatment strategy based on liquid-biopsy-based 
gene profiling.14  
Pretreatment samples showed high TMB, indicating that the tumors might have exhibited 
genome instability. A recent study reported correlations between high TMB and high 
microsatellite instability, POLE mutation, or defective DDR genes,15-17 none of which were 
detected in our case. Another study reported overexpression of DDR genes, including 
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PARP1generated DNA repair error.18 Although the precise mechanism remains unknown, such 
genome instability might have existed, which could have induced the heterogeneous evolution. 
Consistently, we observed several mechanisms of resistance, with the ALK G1202R mutation 
identified among samples resulting from different codon changes. The heterogeneous evolution 
of the tumors and the multiple mechanisms of resistance might be the main factors underlying 
the rapid development of resistance. 
In conclusion, we comprehensively analyzed samples derived from a patient with rapidly 
acquired resistance to alectinib. Timely administration of next-generation ALK inhibitors or 
combination therapies could be an effective alternative treatment strategy for drug-resistant 
lung cancers. Further studies are warranted involving patients with lung cancer harboring ALK 
fusion genes and displaying rapidly acquired resistance to alectinib.  
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Figure 1. Patient clinical course and establishment of the ABC-14 and ABC-17 cell lines and 
the PDX model. A, Clinical course of the patient harboring EML4-ALK-positive lung 
adenocarcinoma. B, Immunohistochemistry targeting ALK in the established cell lines (ABC-
14 and ABC-17) and autopsy samples (primary tumors, liver, bilateral kidney, and PDX tumor). 
Scale bar: 50 µm. C, Computed tomography images of the patient: i) before first-line treatment 
with alectinib, ii) 1 month after initiation of alectinib treatment, and iii) 3 months after alectinib 
treatment. Lung primary lesions (top) and liver metastases (bottom). Alec, alectinib; ALK, 
anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4; CDDP, 
cisplatin; Ceri, ceritinib; Criz, crizotinib; meta, metastasis; PDX, patient-derived xenograft; 
PEM, pemetrexed. 
 
Figure 2. Resistance mechanism of the established ABC-14 cell line. A, MTT assays following 
treatment of ABC-14 cells with the indicated concentrations of alectinib and crizotinib. Error 
bars indicate standard error. All experiments were performed in triplicate. B, Effect of alectinib 
or crizotinib treatment on survival signaling in ABC-14 cells. ABC-14 cells were left untreated 
or incubated with alectinib (1, 10, 102, 103, or 104 nM) or crizotinib (1, 10, 102, 103, or 104 nM) 
for 4 h. Lysates were analyzed by western blot. C, FISH analysis of MET amplification in ABC-
14 cells. Red, MET gene; green, CEP7 gene. MET/CEP7 ratio, 5.6. D, Phospho-receptor 
tyrosine kinase arrays for ABC-14 cells. E, AREG concentrations in culture medium. Viable 
supernatant was assessed by enzyme-linked immunosorbent assay. Error bars represent the 
standard error. *P < 0.01. F, Inhibitory effect of combined therapy with ALK inhibitors (500 
nM), an EGFR TKI, and MET inhibitors (1.0 µM, respectively) on the proliferation of ABC-
14 cells (MTT assay) over 96 h. Data represent the mean ± standard error of the mean of three 
independent experiments. *P < 0.01. ALK inhibitors; alectinib and crizotinib; MET inhibitors; 
crizotinib and SGX-523; EGFR TKI; erlotinib. G, Inhibitory effect of combined therapy with 
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ALK inhibitors, an EGFR TKI, and MET inhibitors on survival signaling in ABC-14 cells. 
Cells were left untreated or incubated with alectinib (500 nM) or crizotinib (500 nM) in the 
presence or absence of erlotinib (1.0 µM) or SGX-523 (1.0 µM) for 4 h. Lysates were analyzed 
by western blot. H, Effect of combined therapy with crizotinib and erlotinib on tumor growth 
and body weight in xenograft models. ABC-14 xenograft tumors were treated with 50 
mg/kg/day crizotinib or 25 mg/kg/day erlotinib or combination therapy, respectively. Data from 
vehicle and treated groups were statistically analyzed on day 29. Error bars represent the 
standard error. Curves represent tumor volume (top) and body weight (bottom). *P < 0.05.  
ALK, anaplastic lymphoma kinase; AREG, amphiregulin; EGFR, epidermal growth factor 
receptor; FISH, fluorescence in situ hybridization; MET, MET proto-oncogene receptor 
tyrosine kinase; TKI, tyrosine kinase inhibitor 
 
Figure 3. Resistance mechanism of the established ABC-17 cell line. A, MTT assays following 
treatment of ABC-17 cells with the indicated concentrations of alectinib and crizotinib. H3122 
is a cell line sensitive to alectinib and crizotinib. Error bars represent the standard error. All 
experiments were performed in triplicate. B, Effect of alectinib or crizotinib on survival 
signaling in ABC-17 cells. Cells were left untreated or incubated with alectinib (1, 10, 102, 103, 
or 104 nM) or crizotinib (1, 10, 102, 103, or 104 nM) for 4 h. Lysates were analyzed by western 
blot. C, Direct sequencing of the ALK kinase domain in ABC-14 and ABC-17 cells. D, MTT 
assays following treatment of ABC-17 cells with the indicated concentrations of lorlatinib. 
Error bars represent the standard error. All experiments were performed in triplicate. E, Effect 
of lorlatinib on survival signaling in ABC-14 and ABC-17 cells. Both lines were left untreated 
or incubated with lorlatinib (1, 10, 102, 103, or 104 nM) for 4 h. Lysates were analyzed by 
western blot. F, Effects of ALK inhibitors on tumor growth and body weight in xenograft 
models. ABC-17 xenograft tumors were treated with 10 mg/kg/day alectinib, 50 mg/kg/day 
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crizotinib, or 10 mg/kg/day lorlatinib. Data for vehicle and treated groups were statistically 
analyzed on day 29. Error bars represent the standard error. Curves represent tumor volume 
(top) and body weight (bottom). *P < 0.05. 
ALK, anaplastic lymphoma kinase. 
 
Figure 4. Metastatic features and drug sensitivity in PDX model mice. A, Autopsy findings 
from the PDX model mice. PDX tumors were passaged subcutaneously between NOG mice, 
and mice were sacrificed at 10 weeks after subcutaneous tumor injection. B, Various tumor 
lesions were stained with hematoxylin and eosin (left) or for immunohistochemistry targeting 
ALK (right). Short bars: 500 µm; long bars: 50 µm. C, Metastatic lesions in various xenograft 
types. A total of 5 × 106 ABC-14 cells, ABC-17 cells, or PDX tumor cells were injected 
subcutaneously into mice, followed by sacrifice at 10-weeks post-injection and lesion 
assessment, including counting. D, Effects of ALK inhibitors on tumor growth and body weight 
in xenograft models. PDX tumors were treated with 10 mg/kg/day alectinib, 50 mg/kg/day 
crizotinib, or 10 mg/kg/day lorlatinib. Data from vehicle and treated groups were statistically 
analyzed on day 29. Error bars represent the standard error. Curves represent tumor volume 
(top) and body weight (bottom). *P < 0.05. 
ALK, anaplastic lymphoma kinase; PDX, patient-derived xenograft.  
 
Figure 5. Comprehensive analysis of established cell lines, PDX model tumors, and clinical 
autopsy samples by RNA sequencing. A, Tumor mutation burden calculated using RNA-
sequencing data from clinical samples and established cell lines. Normal lung tissues were 
obtained from other patients who underwent surgical resection for lung cancers.  
B, Summary of the gene characteristics of autopsied specimens.  
Autopsy lung, autopsied sample from the right lung tumor; lt, left; meta, metastatic lesion; rt, 
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right; PDX, patient-derived xenograft. 
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Supplementary Materials and Methods 
Cell lines and reagents 
PC-9 cells (epidermal growth factor receptor: EGFR Ex19 del E746_A750) were purchased 
from the European Collection of Authenticated Cell Cultures in 2014 (Catalogue No.: 
90071810). 293T cells were purchased from RIKEN Cell Bank in 2016 (Resource No.: RBRC-
RCB2202). H3122 cells (EML4-ALK variant 1 E13; A20) were kindly provided by Dr. William 
Pao (Vanderbilt University, Nashville, TN, USA) in 2012. Cell lines were resuscitated at least 
every 3 months from frozen master stocks. 
ABC-14 and ABC-17 cell lines were established at Okayama University Hospital from 51-
y.o. male patient with EML4-ALK-positive NSCLC in 2016. ABC-14 was established from 
pleural effusion following alectinib therapy (Fig. 1A) as described previously1. Numerous tumor 
clusters were observed cytologically in the effusion. Mononuclear cells were isolated from the 
malignant effusion using the Ficoll–Hypaque method and washed twice with RPMI-1640 
medium. The cells were suspended in a 6-well dish with RPMI-1640 medium supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin and began growing within several weeks 
and proliferated consistently thereafter. ABC-17 was derived from PDX tumors, which were 
established from a liver metastatic tumor harvested upon autopsy (Fig. 1A). The liver metastasis 
sample was minced and injected subcutaneously into the back of a female NOG mouse 
(NOD/Shi-scid, IL-2RγKO Jic) purchased at 6 weeks of age from In-Vivo Science, Japan for the 
PDX model. Two months after the injection without drug treatment, the subcutaneous tumor 
grew up and was minced and washed twice with RPMI 1640 medium. To eliminate mouse 
fibroblast cells and establish the purified tumor cell line, ABC-17, we used the Mouse Cell 
Depletion Kit (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer’s protocol. 
PDX tumors were homogenized using the Tumor Dissociation Kit, human (Cat. No. 130-095-
929, Miltenyi Biotec) and transplanted from mouse to mouse by injecting homogenized cells 
subcutaneously into the backs of the mice. Written informed consent was obtained from the 
patient and his family and the Institutional Review Board of Okayama University approved this 
experiment (approval no. 1603-066). The animal experimental protocol was approved by the 
Animal Care and Use Committee, Okayama University, Okayama, Japan (OKU-2017085). Cells 
were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin in a tissue culture incubator at 37.0 C under 5% CO2. All cell lines are 
tested for mycoplasma using e-Myco™ Mycoplasma PCR detection kit (Intron Biotechnology, 
Seongnam, Korea). 
Crizotinib and SGX-523 were purchased from Selleck Chemicals (Houston, TX, USA), 
erlotinib from LC laboratories (Woburn, MA, USA), and lorlatinib (PF 06463922) from Toronto 
Research Chemicals (Toronto, Canada).  
 
Drug sensitivity assays 
Growth inhibition was measured using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells were plated onto 96-well plates at a density of 
4,000 per well and continuously exposed to each drug for 96 h 2. Analysis was performed 
running a nonlinear regression (curve fit) method in GraphPad Prism 7 for windows (GraphPad 
Software, San Diego, CA, USA). 
 
Direct sequencing and mRNA expression analysis 
RNA was extracted from cells using an RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s protocol. Direct sequencing was conducted as described 
previously 3. RNA expression was analyzed by real time quantitative reverse transcription-PCR 
(qRT-PCR) of cDNA using TaKaRa SYBR Premix Ex Taq II (Tli RNase H Plus) (TaKaRa), 
according to the manufacturer’s protocol. The primer information is provided in Supplementary 
Table S6. 
 
Fluorescence in situ hybridization (FISH) 
FISH was performed on formalin-fixed, paraffin-embedded samples by SRL Inc. (Tokyo, 
Japan) using a break-apart probe for the ALK gene (Vysis Break Apart Rearrangement Probe; 
Abbott Laboratories, Abbott Park, IL, USA), or MET SpectrumRed and CEP7 SpectrumGreen 
probes, respectively. ALK fusion positive was defined as > 15% split signals in cells. MET gene 
amplification was defined as MET/CEP7 ratio > 5. 
 
Immunohistochemistry (IHC) 
IHC was conducted as described previously 4. Antibodies information is provided in 
Supplementary Table S7.  
 
Western blotting and receptor tyrosine kinase assay 
Western blotting was conducted as described previously 3, 5. Antibodies information is 
provided in Supplementary Table S8. A Human Phospho-Receptor Tyrosine Kinase (RTK) 
Array Kit was purchased from R&D Systems (Minneapolis, MN, USA) and used according to 
the manufacturer’s recommendations. Bands and dots were detected using an ImageQuant LAS-
4000 imager (GE Healthcare Biosciences). 
 Xenograft models 
Female BALB/c-nu/nu mice were purchased at 7 weeks of age from Charles River 
Laboratories, Yokohama, Japan. Cells (5 × 106) (ABC-14 or ABC-17) were injected 
subcutaneously into the backs of the mice. Treatment was started when the tumor reached 
approximately 250 mm3 (day 0). Mice were randomized to receive vehicle, alectinib (10 
mg/kg/day), crizotinib (50 mg/kg/day), erlotinib (25 mg/kg/day), or crizotinib + erlotinib for the 
same duration for ABC-14 xenograft model mice. ABC-17 xenograft model mice were 
randomized to receive vehicle, alectinib, crizotinib, or lorlatinib (10 mg/kg/day). The vehicle and 
drugs were administered once daily, five times per week by gavage. Tumor volume (width2 × 
length/2) was determined periodically. Statistical data were analyzed on day 28.  
All experiments involving animals were performed under the auspices of the Institutional 
Animal Care and Research Advisory Committee at the Department of Animal Resources, 
Okayama University Advances Sciences Research. The experimental protocol was approved by 
the Animal Care and Use Committee, Okayama University, Okayama, Japan (OKU-2017084, 
2017085). 
 
Statistical analysis 
All statistical analyses were conducted using STATA/SE ver. 14.0 (College Station, TX, 
USA). Inter-group differences were analyzed by the two-tailed paired Student’s t-test (group = 2) 
and the ANOVA Bonferroni’s Multiple Comparison Test (group ≥ 3). P-value of <0.05 was 
considered significant. 
 
mRNA expression profiling and tumor mutation burden analysis by NGS 
Frozen lung tissues and metastatic lesions were obtained at the time of autopsy, immediately 
frozen in liquid nitrogen, and stored until use. RNA was extracted from frozen tissues using an 
RNeasy Mini Kit (Qiagen) according to manufacturer protocol. cDNA libraries were prepared 
using the TruSeq RNA Access Library Prep Kit (Illumina, San Diego, CA, USA) and RNA 
sequencing was performed on a HiSeq Sequencing System. Sequencing data were mapped and 
analyzed to calculate TPM (Transcripts Per Kilobase Million) values using the CLC Genomics 
Workbench (CLC bio, Aarhus, Denmark). Fifty hallmark gene sets obtained from the Gene Set 
Enrichment Analysis molecular-signatures database (v.6.2; 
http://software.broadinstitute.org/gsea/msigdb/index.jsp) were used to extract genes representing 
well-defined biological states of processes. Hierarchical clustering was performed and displayed 
by using cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) and Java 
treeview (http://jtreeview.sourceforge.net/). Based on the similarity in gene-expression patterns 
of cancer-related genes, an unrooted phylogenetic tree was analyzed using the hclust and 
as.phylo functions and displayed using the plot function in the RStudio environment 
(https://www.rstudio.com/). Tumor mutation burden (TMB) was calculated using the selected 
341 genes in MSK-IMPACT ver 1 according to a previous report 6. Briefly, we extracted the 
number of mutations in the selected gens from the NGS data. TMB was calculated by dividing 
the number of mutations by the total genomic area where mutations were reported (0.98 Mb). 
The threshold of high TMB was defined as over 13.8 mutations/Mb. RNA-seq data are available 
in the NCBI Sequence Read Archive (SRA) repository (PRJNA545223). 
 
Targeted deep sequencing of the ALK kinase domain using NGS  
Frozen lung cancer tissues and metastatic lesions were obtained at the time of autopsy, 
immediately frozen in liquid nitrogen, and stored until use. Genomic DNA from freshly frozen 
tissue samples was extracted using a QIAmp DNA mini Kit (Qiagen) according to manufacturer 
instructions. Target enrichment was performed using 100 ng of input DNA using the HaloPlexHS 
system (Agilent Technologies, Santa Clara, CA, USA), which is a high-sensitivity, amplicon-
based targeted sequencing method. The library was prepared based on manufacturer instructions 
for ClearSeq Cancer HS, ILM, which was designed to identify somatic variants in 47 cancer-
related genes targeting known COSMIC hotspots found to be associated with a various types of 
cancers. Sequencing was performed using the MiSeq version 3 600-cycle kit (Illumina, San 
Diego, CA, USA) according to manufacturer instructions for paired-end sequencing (2 × 300 
cycles). 
The generated sequences were processed in-house using Agilent SureCall software (Agilent 
Technologies), which is used exclusively with the HaloPlexHS system. Amplicon-based targeted 
sequencing data are available in the NCBI SRA repository (PRJNA545223). 
 
Quantification of amphiregulin (AREG) by ELISA 
Cells (2×105) were cultured in RPMI-1640 medium with 10% FBS for 24 h, washed with 
PBS, and incubated for 48 h in 2 mL of the same medium. The culture medium was harvested 
and centrifuged, and the supernatant was stored at −80 C until analysis. The level of AREG was 
determined using Quantikine ELISA kits (R&D Systems) in accordance with the manufacturer’s 
protocols. All culture supernatants were tested twice. Color intensity was measured at 450 nm 
using a spectrophotometric plate reader (Bio-Rad Model 680). The concentration of AREG was 
determined in comparison to the standard curve.  
 Combination Index Analysis 
The constant-ratio design for the combination assay is highly recommended as it allows the 
most efficient data analysis 7. The multiple drug effect analysis developed by Chou and Talaly, 
based on the median-effect principle, was used to calculate the combined drug effect 8. ABC-14 
cells were seeded in triplicate in 96-well plates and were treated with alectinib and SGX-523 or 
crizotinib and erlotinib at the indicated concentrations for 96 hours. Cell viability was assessed 
using the MTT assay. The combination indices (CIs) were calculated using the CompuSyn 
software (Combosyn; Paramus, NJ, USA) as developed by Chou TC et al. in 2010 9. The plots 
generated by the CompuSyn software demonstrate the Y-axis CIs, where CI <1, =1, and >1 
indicate synergism, additive effect, and antagonism, respectively. The X-axis represents the 
fractional activity, which reflects the fraction of cells inhibited by the treatments relative to the 
vehicle control. 
  
Supplementary Figure S1.  
Clinical course of brain metastases. (i) Brain metastases at initiation of alectinib treatment. There 
were two brain metastases: one on the temporal lobe and the other on the parietal lobe. (ii) Brain 
metastases 1.5 months after alectinib treatment. Both metastases shrank after treatment. After 
failure of alectinib treatment, the lesions did not progress according to contrast-enhanced 
computed tomography (not shown). (iii) Brain metastases after cisplatin/pemetrexed treatment 
(before ceritinib treatment). A new brain metastasis was observed on the frontal lobe. (iv) Brain 
metastases after ceritinib treatment. Contrast-enhanced MRI was not be performed due to the 
allergic side effects elicited by the contrast agent. Brain metastasis was not evident. 
 
Supplementary Figure S2.  
Characteristics of the clinical samples and established cell lines. A, Pathological findings and 
FISH analysis of ALK (red, ALK 3-; green, ALK 5-) of the primary right lung tumor biopsy 
specimen (scale bars: 50 µm). B, Microscopic images of established cell lines, ABC-14 and 
ABC-17 (scale bars: 100 µm). C, EML4-ALK fusion sequence of established cell lines (ABC-14, 
ABC-17) and autopsy samples (primary lung, bilateral kidney, PDX tumor) detected by Sanger 
sequencing. Primary lung; transbronchial biopsy sample from primary right lung tumors, 
Autopsy lung; autopsied sample from right lung tumor, meta; metastatic lesion 
 
Supplementary Figure S3.  
BIM deletion check by Sanger sequence PCR in ABC-14 and ABC-17 cell lines. A, Schematic 
image of the BIM deletion polymorphism and the Sanger sequencing PCR of the deleted portion 
of BIM in ABC-14 and ABC-17 cell lines. B, Electrophoresis image of BIM PCR products. PC-9 
(BIM deletion negative control), ABC-14, and ABC-17 cell lines were all negative for the BIM 
deletion polymorphism. 
 
Supplementary Figure S4.  
RNA sequencing data analysis. A, Gene expression profile in transbronchial biopsy sample from 
primary right lung tumor, primary cardiac effusion, established cell lines (ABC-14, ABC-17), 
subcutaneous tumor of the PDX model mouse, and the autopsy samples by RNA-sequencing. 
TPM values were calculated with CLC Genomics Workbench (CLC Bio, Aarhus, Denmark). B, 
RNA sequencing data of ALK kinase domain in established cell lines (ABC-14, ABC-17) and 
PDX model tumor. The sequencing data are focused on the G1202R point mutation in all 
samples (pointed as arrow). C, RNA sequencing data of the ALK kinase domain in primary 
tissue samples, pericardial effusion and autopsy tissue samples. Sequencing data focused on the 
G1202R point mutation in all samples (arrows). D, Patterns of ALK mutations resulting in the 
G1202R substitution in clinical samples according to Sanger sequencing.  
ALK, anaplastic lymphoma kinase; autopsy lung, autopsied sample from the right lung tumor; lt, 
left; meta, metastatic lesion; NGS, next-generation sequencing; primary lung, transbronchial 
biopsy sample from primary right lung tumors; rt, right; TPM, transcripts per kilobase million. 
 
Supplementary Figure S5.  
Resistance mechanism of ABC-14. A, IHC for MET of ABC-14 and ABC-17 cell lines (scale 
bars: 50 µm). B, Comparison of the expression of MET and EGFR protein between ABC-14 and 
ABC-17 cell lines by western blotting. C, Phospho-receptor tyrosine kinase assays for ABC-17 
cells. D, combination index analysis of ABC-14 cells treated with alectinib in combination with 
SGX-523 (blue curve) and with crizotinib in combination with erlotinib (red curve) 
simultaneously for 96 hours at molar ratios of 1:2 (alectinib:SGX-523 and crizotinib:erlotinib). 
Synergistic effects in ABC-14 cells are shown. 
 
Supplementary Figure S6.  
Resistance mechanism of ABC-17. A, Evaluation of EMT of established cell lines, ABC-14 and 
ABC-17, by western blotting. PC-9 cell is positive control of E-cadherin, and 293T cell is a 
positive control of vimentin. B, Evaluation of EMT of established cell lines, ABC-14, ABC-17, 
liver metastasis, and PDX tumor, by immunohistochemistry. The upper columns are E-cadherin, 
and the bottom columns are vimentin (scale bars: 50 µm). 
 
Supplementary Figure S7.  
Gene expression profiles using RNA sequencing 
A, Expression of DNA damage repair genes in the primary transbronchial biopsy sample, 
primary cardiac effusion, established cell lines (ABC-14, ABC-17), subcutaneous tumor of the 
PDX model mouse, and the primary and the metastatic lesion of the autopsy samples B, Heat 
map image of gene expression profiles in the primary transbronchial biopsy sample, primary 
cardiac effusion, established cell lines (ABC-14, ABC-17), subcutaneous tumor of the PDX 
model mouse, and the primary and the metastatic lesion of the autopsy samples. The red color 
shows high gene expression and the blue color shows low gene expression in the heat map 
image. C, Phylogram image of gene-expression profile in the transbronchial biopsy sample, 
pericardial effusion, subcutaneous tumor of the PDX model mouse, and the autopsy samples by 
RNA sequencing. Autopsy lung, autopsied sample from right lung tumor; lt, left; Primary lung, 
transbronchial biopsy sample from primary right lung tumors; meta, metastatic lesion; rt, right; 
TPM, transcripts per kilobase million. 
 
Supplementary Figure S8.  
Targeted deep sequencing of the ALK kinase domain using HaloPlexHS 
A, B, Targeted deep sequencing data of ALK kinase domain in alectinib resistant plural effusion 
and autopsy tissue samples. Autopsy lung, autopsied sample from right lung tumor; lt, left; meta, 
metastatic lesion; rt, right. 
 
Supplementary Figure S9. Summary of the mechanisms of therapeutic resistance. A,B, 
Mechanisms of therapeutic resistance in the established cell lines (ABC-14, ABC-17, and PDX 
tumors). ABC-14 cells displayed MET gene amplification and increased AREG secretion. The 
ALK G1202R mutation was present in ABC-17 cells and PDX tumors. Combined therapy with 
crizotinib and erlotinib or lorlatinib treatment represent potential treatment strategies for 
overcoming therapeutic resistance. Alec, alectinib; Crizo, crizotinib. 
 Supplementary Table S1. Clinical response to alectinib therapy. 
 
Target lesion (mm) Baseline Best overall response 
(Day 44) 
Progressive disease 
(Day 107) 
Primary lung 41.7 23.8 17.0 
Liver metastasis 42.3 10.5 51.4 
Left renal metastasis 41.2 17.7 15.9 
Left adrenal metastasis 42.9 25.5 20.8 
Right renal metastasis 48.5 22.0 25.3 
Total (mm) 216.6 99.5 (−54.1%) 130.4 (+31.1%) 
    
Non-target lesion    
Plural effusion  CR CR 
Brain  CR CR # 
Mediastinal lymph nodes  nonCR/nonPD  
    
New Lesion  No No 
# Brain lesions were evaluated with enhanced computed tomography at the point.  
CR, complete response; PD, progressive disease  
Supplementary Table S2. Clinical response to cisplatin/pemetrexed therapy. 
 
Target lesion (mm) Baseline Best overall response 
(Day 45) 
Progressive disease 
 (Day 133) 
Primary lung 13.1 10.9 13.9 
Liver meta#1 42.3 14.5 29.0 
Liver meta#2 27.7 12.5 11.1 
Left adrenal meta 21.8 18.2 21.3 
Right renal meta 37.3 12.4 51.3 
Total (mm) 142.2 68.5 (-51.9%) 126.6 (+84.8%) 
    
Non target    
Brain   PD 
Liver meta#3  nonCR/nonPD PD 
    
New lesion  No No 
CR, complete response; PD, progressive disease  
Supplementary Table S3. Clinical course of ceritinib therapy. 
 
Treatment day Clinical course 
Day 1 Ceritinib 750 mg/day 
Day 15 Drug withdrawal due to Gr2 nephrotoxicity 
Day 19 Restart with ceritinib 750 mg/day 
Day 28 Drug withdrawal due to Gr2 nephrotoxicity 
Day 31 Discontinuance due to Gr3 anorexia and disease progression  
Gr, Grade  
Supplementary Table S4. Mutations in genes used to calculate TMB in pretreated lung cancer. 
Chromosome Gene Name Region Type Reference Allele 
1 SDHB 17024074 SNV C T 
1 MUTYH 45333296 SNV C T 
2 MSH2 47412436 SNV T C 
2 MSH6 47799512 SNV G A 
2 CASP8 201272669 SNV A G 
2 BARD1 214730491 SNV G A 
3 MLH1 37020350 SNV C T 
5 APC 112842867 SNV A G 
5 CSF1R 150054324 SNV G A 
7 PMS2 5977709 SNV T C 
7 PMS2 5982890 SNV G A 
7 PMS2 5987189 SNV C T 
7 MET 116731699 SNV C T 
8 NBN 89958806 SNV A G 
9 PTCH1 95449242 SNV G A 
9 TGFBR1 99138080 SNV G A 
9 TSC1 132903756 SNV C A 
10 FGFR2 121488002 SNV T C 
11 ATM 108257583 SNV C T 
11 ATM 108267246 SNV G A 
11 ATM 108279499 SNV A G 
16 TSC2 2065526 SNV C T 
16 TSC2 2065541 SNV C G 
16 TSC2 2070559 SNV C T 
16 TSC2 2079567 SNV G A 
16 CDH1 68829727 SNV C T 
16 CDH1 68833497 SNV T C 
17 TP53 7675056 SNV C T 
17 NF1 31226505 SNV T C 
17 NF1 31233137 SNV T G 
17 NF1 31261810 SNV G A 
17 BRCA1 43071164 SNV C A 
19 JAK3 17838329 SNV C A 
 
 
Supplementary Table S5. Mutation pattern in pretreated lung cancer. 
Transversion : Transition = 5 : 28 (%Transition = 84.8%) 
Ref Allele 
 A T G C Total 
A 0 0 4 0 4 
T 0 0 1 5 6 
G 9 0 0 0 9 
C 3 10 1 0 14 
Total 12 10 6 5 33 
  
Supplementary Table S6. Primer sequences 
(A) EML4-ALK Direct sequencing analysis (mRNA) 
No.1 Forward 
Reverse 
5’-CGGTCCGCTGAATGAAGT-3’ 
5’-GGTGGGAGTAGCATTCTTGC-3’ 
 No.2 Forward 
Reverse 
5’-CCCTCTTCACAACCTCTCCA-3’ 
5’-TCGTCCTGTTCAGAGCACAC-3’ 
No.3 Forward 
Reverse 
5’-AGGTGTATGAAGGCCAGGTG-3’ 
5’-TCCACTGGTGACAAACTCCA-3’ 
No.4 Forward 
Reverse 
5’-GGTCCTTTGGAGTGCTGCTA-3’ 
5’-TAAACCAGGAGCCGTACGTT-3’ 
No.5 Forward 
Reverse 
5’-ACCTCTGCCTACCACCTCCT-3’ 
5’-GGGATCCCAAGGAAGAGAAG-3’ 
(B) BIM deletion direct sequencing analysis (DNA) 
Wild Type Forward 
Reverse 
5’-CCACCAATGGAAAAGGTTCA-3’ 
5’-CTGTCATTTCTCCCCACCAC-3’ 
Deletion Forward 
Reverse 
5’-CCACCAATGGAAAAGGTTCA-3’ 
5’-GGCACAGCCTCTATGGAGAA-3’ 
 
Supplementary Table S7. Antibodies for immunohistochemistry 
Antibodies Source Identifier 
ALK Abcam ab17127 
MET Cell Signaling Technology 8198 
E-Cadherin Cell Signaling Technology 3195 
Vimentin Cell Signaling Technology 5741 
 
Supplementary Table S8. Antibodies for western blotting 
Antibodies Source Identifier 
Phospho-ALK (Tyr1604) Cell Signaling Technology 3341 
ALK Invitrogen 51-3900 
Phospho-STAT3 (Tyr705) Cell Signaling Technology 9145 
STAT3 Cell Signaling Technology 4904 
Phospho-EGFR (Tyr1068) Cell Signaling Technology 3777 
EGFR Cell Signaling Technology 2232 
Phospho-MET (Tyr1234/1235) Cell Signaling Technology 3077 
MET Cell Signaling Technology 8198 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
Cell Signaling Technology 9101 
p44/42 MAPK (Erk1/2) Cell Signaling Technology 9102 
Phospho-Akt (Ser473) Cell Signaling Technology 9271 
Akt Cell Signaling Technology 9272 
E-Cadherin Cell Signaling Technology 3195 
Vimentin Cell Signaling Technology 5741 
GAPDH Cell Signaling Technology 2118 
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A Gene Name ABC-14 ABC-17 Primary lung Pericardial effusion Autopsy lung Autopsy liver meta NOG PDX 3rd Autopsy lt. renal meta Autopsy rt. renal metaEML4 29 22 41 29 37 7 2 27 14
ALK 14 19 5 2 5 6 1 1 6
MET 2,276 275 178 46 47 22 14 27 65
HGF 0 0 19 1 5 2 0 5 0
EGFR 124 66 59 11 53 34 4 23 47
EGF 14 9 4 1 5 6 1 5 4
TGFA 4 0 1 0 0 1 1 1 3
AREG 949 6 39 70 136 5 96 32 120
HBEGF 2 19 7 3 7 3 3 4 3
BTC 1 0 1 0 0 0 0 0 0
EREG 27 1 0 1 1 1 4 0 5
EPGN 0 0 0 0 0 2 0 0 0
VIM 48 2,638 1,684 552 1,119 126 29 512 456
CDH1 454 1 210 24 39 27 15 42 108
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ALK Gly1202Arg
Codon 1202 Ref Allele Mutation count Total read No. % mutation
Alectinib resistant pleural effusion GGA G G 0 28 -
Autopsy lung AGA G A 2 55 3.64
Autopsy lt. renal meta GGA G G 0 56 -
Autopsy rt. renal meta CGA G C 6 88 6.82
Autopsy liver meta AGA G A 12 51 23.5
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